InBrain Pharma, a biotechnology start-up developing therapeutic solutions for neurodegenerative diseases, is the winner of the Deep Tech development grant.
The first start-up in the Hauts-de-France region to receive this support, InBrain Pharma, in collaboration with Lille University Hospital, the University of Lille, and INSERM, will be able to conduct an initial clinical trial on patients with advanced and debilitating Parkinson's disease.
"Beyond financial assistance, this support demonstrates the innovative and groundbreaking nature of our approach, which was initially developed by academic researchers in Lille. This support from BPIFrance is
a strong signal regarding the scientific, medical, societal, and commercial potential of our approach," said Dr. Matthieu Fisichella, CEO of InBrain Pharma. This vision is confirmed by Ms. Descamps, Innovation Business Manager at BPIFrance:
"This is a wonderful project that deserves our support. It represents a real potential breakthrough in the symptomatic treatment of Parkinson's disease compared to the second-line treatments
currently on the market. It is being developed by a team with recognized expertise. This disruptive technology also offers prospects for other diseases."
The first technology developed by InBrain Pharma involves continuously administering the missing dopamine directly into patients' brains, similar to how insulin is administered to treat diabetes. This "Brain Infusion" concept will then be applied to other treatments to improve the management of brain diseases.
https://www.inbrainpharma.com/